The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
In the citing paper
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
In the citing paper
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
In the citing paper
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
Flagged first, then by citations
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
Items 401–500 of 942
Ballesio, A., Zagaria, A., Vacca, M., Pariante, C. M., & Lombardo, C. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.05.006 · Cited by 30
Influence of gut microbiota on resilience and its possible mechanisms
Wang, J., Zhou, T., Liu, F., Huang, Y., Xiao, Z., Qian, Y., & Zhou, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82362 · Cited by 30
Al‐Hakeim, H. K., Twayej, A. J., Al-Dujaili, A. H., & Maes, M. H. J. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200102100307 · Cited by 30
Rein, T., Ambrée, O., Fries, G. R., Rappeneau, V., Schmidt, U., & Touma, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00009-3 · Cited by 29
Ioannou, M., Foiselle, M., Mallet, J., Stam, E. L., Godin, O., Dubertret, C., Terro, E., Sommer, I. E., Haarman, B. C. M., Leboyer, M., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.001 · Cited by 28
Nutritional therapy can reduce the burden of depression management in low income countries: A review
Ekong, M. B., & Iniodu, C. F. (2021) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2021.06.002 · Cited by 28
Mao, L., Ren, X., Wang, X., & Tian, F. (2022) · Journal of Immunology Research · doi:10.1155/2022/6724881 · Cited by 28
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
Burchett, J. R., Dailey, J. M., Kee, S. A., Pryor, D. T., Kotha, A., Kankaria, R. A., Straus, D. B., & Ryan, J. J. (2022) · Cells · doi:10.3390/cells11193031 · Cited by 34
Kronsten, V. T., & Shawcross, D. L. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114437 · Cited by 27
Depressive-like behaviors in mice with Imiquimod-induced psoriasis
Guo, J., Liu, Y., Guo, X., Meng, Y., Qi, C., Zhao, J., Di, T., Zhang, L., Guo, X., Wang, Y., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107057 · Cited by 29
Karczewski, J., Zielińska, A., Staszewski, R., Eder, P., Dobrowolska, A., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116145 · Cited by 27
Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder
Wiener, C. D., Moreira, F. P., Cardoso, T. A., Mondin, T. C., Magalhães, P. V. D. S., Kapczinski, F. P., Souza, L. D. D. M., da Silva, R. A., Oses, J. P., & Jansen, K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.03.003 · Cited by 26
Plasma IL-17A levels in patients with late-life depression
Saraykar, S., Cao, B., Barroso, L., Pereira, K. S., Bertola, L., Nicolau, M. D. S., Ferreira, J. D. R., Dias, N. S., Vieira, É. L. M., Teixeira, A. L., et al. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-2299 · Cited by 25
Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults
Grassi, G., & Pallanti, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528230 · Cited by 27
Al-Dujaili, A. H., Al‐Hakeim, H. K., Twayej, A. J., & Maes, M. H. J. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00458-5 · Cited by 25
Forbes, M., O'Neil, A. E., Lane, M. M., Agustini, B., Myles, N., & Berk, M. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00858-2 · Cited by 25
Su, W., Hu, T., & Jiang, C. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809112028 · Cited by 27
Caneo, C., Marston, L., Bellón, J. Á., & King, M. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2016.09.007 · Cited by 26
Association between hs-CRP and depressive symptoms: a cross-sectional study
Ji, Y., Wang, J., Chen, H., Li, J., & Chen, M. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1339208 · Cited by 27
Liang, M., Du, Y., Li, W., Yin, X., Ni, Y., Qie, A., LeBaron, T. W., Zhang, J., Chen, H., & Shi, H. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00082 · Cited by 25
Involvement of inflammatory gene expression pathways in depressed patients with hyperphagia
de Kluiver, H., Jansen, R., Milaneschi, Y., & Penninx, B. W. J. H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0528-0 · Cited by 26
Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson’s Disease
Tran, A. A., Smet, M. D., Grant, G. D., Khoo, T. K., & Pountney, D. L. (2020) · Complex Psychiatry · doi:10.1159/000512657 · Cited by 29
Rengasamy, M. L., Marsland, A. L., Spada, M. L., Hsiung, K. S., Kovats, T., & Price, R. B. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100177 · Cited by 29
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 28
Lombardo, G., Nettis, M. A., Hastings, C. N. M., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A. P., Kose, M., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100561 · Cited by 26
Husain, M. I., Chaudhry, I. B., Hamirani, M. M., Minhas, F., Kazmi, A., Hodsoll, J. P., Haddad, P. M., Deakin, J. F. W., Husain, N., & Young, A. H. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s115002 · Cited by 25
Zheng, X.-X., Zhang, C., Li, L.-Q., Ye, J.-R., Ren, S., Zhang, Z., He, X., Chu, S., & Chen, N. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110871 · Cited by 24
Gruenbaum, B. F., Schonwald, A., Boyko, M., & Zlotnik, A. A. (2024) · Cells · doi:10.3390/cells13141228 · Cited by 26
Almulla, A. F., & Maes, M. H. J. (2025) · CNS Drugs · doi:10.1007/s40263-025-01195-3 · Cited by 29
Askari, G., Aghajani, M., Salehi, M., Najafgholizadeh, A., Keshavarzpour, Z., Fadel, A., Venkatakrishnan, K., Salehi‐Sahlabadi, A., Hadi, A., & Pourmasoumi, M. (2020) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2020.100364 · Cited by 26
Genetic evidence for causal effects of immune dysfunction in psychiatric disorders: where are we?
Iakunchykova, O. P., Leonardsen, E. H., & Wang, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02778-2 · Cited by 24
Matured Hop Bitter Acids in Beer Improve Lipopolysaccharide-Induced Depression-Like Behavior
Fukuda, T., Ohya, R., Kobayashi, K., & Ano, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00041 · Cited by 24
A clinical model for identifying an inflammatory phenotype in mood disorders
Kramer, N. E., Cosgrove, V. E., Dunlap, K., Subramaniapillai, M., McIntyre, R. S., & Suppes, T. M. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.02.005 · Cited by 27
Animal models of major depressive disorder and the implications for drug discovery and development
Demin, K. A., Sysoev, M., Chernysh, M. V., Savva, A. K., Koshiba, M., Wappler-Guzzetta, E. A., Song, C., de Abreu, M. S., Leonard, B. E., Parker, M. O., et al. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1575360 · Cited by 24
Li, M.-L., Chen, Z., Liu, Z.-Z., Zhang, N., Liu, J., Wang, H.-R., Wang, W., Liang, Y., Chen, J.-W., Liu, Z., et al. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2441-8 · Cited by 22
Giollabhui, N. M., Madison, A. A., Lydston, M., Quang, E. L., Miller, A. H., & Liu, R. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241115 · Cited by 28
Leavitt, V. M., Meo, E. D., Riccitelli, G. C., Rocca, M. A., Comı, G., Filippi, M., & Sumowski, J. F. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7863-8 · Cited by 23
Hernandez, N. V., Ramirez, J. L., Khetani, S. A., Spaulding, K. A., Gasper, W. J., Hiramoto, J. S., Lindqvist, D., Wolkowitz, O. M., Hills, N. K., Grenon, S. M., et al. (2018) · Vascular Medicine · doi:10.1177/1358863x18787640 · Cited by 22
Huang, Y., Wang, Y., Hu, K., Lin, S., & Lin, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.667773 · Cited by 23
Xiao, Y.-G., Wu, H.-B., Chen, J., Li, X., & Qiu, Z.-K. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00930-9 · Cited by 23
Neuroinflammation in the Amygdala Is Associated With Recent Depressive Symptoms
Zhang, W., Rutlin, J. R., Eisenstein, S. A., Wang, Y., Barch, D. M., Hershey, T. G., Bogdan, R., & Bijsterbosch, J. D. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.04.011 · Cited by 24
Brunoni, A. R., Machado‐Vieira, R., Sampaio-Júnior, B., Vieira, É. L. M., Valiengo, L. D. C. L., Benseñor, I. M., Lotufo, P. A., Carvalho, A. F., Cho, H. J., Gattaz, W. F., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.006 · Cited by 26
The Predictive Value of Depressive Symptoms for All-Cause Mortality
Hughes, M., Patterson, C., Appleton, K. M., Blankenberg, S., Woodside, J. V., Donnelly, M., Linden, G. J., Zeller, T., Esquirol, Y., & Kee, F. (2016) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000289 · Cited by 22
Proteomic investigation of the prefrontal cortex in the rat clomipramine model of depression
Gellén, B., Völgyi, K., Györffy, B. A., Darula, Z., Hunyadi‐Gulyás, É., Baracskay, P., Czurkó, A., Hernádi, I., Juhász, G. D., Dobolyi, Á., et al. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.06.027 · Cited by 25
Stirton, H., Meek, B. P., Edel, A. L., Solati, Z., Surendran, A., Aukema, H. M., Modirrousta, M., & Ravandi, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246592 · Cited by 23
Depressive symptoms, childhood maltreatment, and allostatic load: The importance of sex differences
O’Shields, J., & Gibbs, J. J. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105130 · Cited by 22
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2021) · Focus · doi:10.1176/appi.focus.19304 · Cited by 22
Qi, Y., Lu, Y.-R., Shi, L., Demmers, J., Bezstarosti, K., Rijkers, E., Balesar, R. A., Swaab, D. F., & Bao, A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02040-7 · Cited by 21
do Vale, E. M., Xavier, C. C., Nogueira, B. G., Campos, B. C., de Aquino, P. É. A., da Costa, R. O., Leal, L. K. A. M., Vasconcelos, S. M. M., Neves, K. R. T., & Viana, G. S. D. B. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12637 · Cited by 22
Todorović, N., & Filipović, D. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.04.044 · Cited by 24
Allison, D. J., Sharma, B., & Timmons, B. W. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.05.006 · Cited by 21
Teixeira, A. L., Martins, L. B., Berk, M., & Bauer, M. E. (2022) · Clinical Science · doi:10.1042/cs20211106 · Cited by 22
Kelly, D. L., Syrjala, K. L., Taylor, M. R., Rentscher, K. E., Hashmi, S. K., Wood, W. A., Jim, H., Barata, A., Flynn, K. E., Burns, L. J., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.007 · Cited by 21
Tateishi, H., Mizoguchi, Y., & Monji, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.834425 · Cited by 21
Neurobiological Mechanisms Of Depression Following Traumatic Brain Injury
Jahan, A. B., & Tanev, K. S. (2022) · Brain Injury · doi:10.1080/02699052.2022.2145362 · Cited by 22
Rakshasa-Loots, A. M., Bakewell, N., Sharp, D. J., Gisslén, M., Zetterberg, H., Alagaratnam, J., Wit, F. W. N. M., Kootstra, N. A., Winston, A., Reiss, P., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02489-0 · Cited by 22
NLRP3 inflammatory pathway. Can we unlock depression?
Jahromi, G. G., Razi, S., & Rezaei, N. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148644 · Cited by 24
McCallum, R. T., Thériault, R.-K., Manduca, J. D., Russell, I. S. B., Culmer, A. M., Doost, J. S., Martino, T. A., & Perreault, M. L. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00589-0 · Cited by 21
Invisible Designers: Brain Evolution Through the Lens of Parasite Manipulation
Giudice, M. D. (2019) · The Quarterly Review of Biology · doi:10.1086/705038 · Cited by 21
Subramaniapillai, M., Carmona, N. E., Rong, C., & McIntyre, R. S. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rmcintyre · Cited by 21
Murphy, J., Zierotin, A., Mongan, D., Healy, C., Susai, S. R., O'Donoghue, B. N., Clarke, M., O’Connor, K., Cannon, M. D., & Cotter, D. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.06.003 · Cited by 20
Salte, K., Titlestad, I. L., & Halling, A. (2015) · PubMed · Cited by 20
The Pelvic Girdle Pain deadlock: 2. Topics that, so far, have remained out of focus
Meijer, O. G., Barbe, M. F., Prins, M. R., Schipholt, I. J. L., Hu, H., & Daffertshofer, A. (2020) · Musculoskeletal Science and Practice · doi:10.1016/j.msksp.2020.102166 · Cited by 22
Yoga in major depressive disorder: molecular mechanisms and clinical utility
Tolahunase, M., Gautam, S., Sagar, R., Kumar, M., & Dada, R. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s553 · Cited by 22
Tang, Y., Illes, P., Zhang, Y., Yin, H.-Y., & Rubini, P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220302152400 · Cited by 20
The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 20
Understanding the development of chronic loneliness in youth
Hang, S., Jost, G. M., Guyer, A. E., Robins, R. W., Hastings, P. D., & Hostinar, C. E. (2023) · Child Development Perspectives · doi:10.1111/cdep.12496 · Cited by 28
Elnahas, E. M., Zeid, M. S. A., Kawy, H. S. A., Hendawy, N., & Baher, W. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.027 · Cited by 20
BPCO, troubles anxio-dépressifs et cognitifs : l’inflammation joue-t-elle un rôle prépondérant ?
Peiffer, G., Underner, M., Perriot, J., & Fond, G. B. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.03.004 · Cited by 22
Yamauchi, T., Makinodan, M., Toritsuka, M., Okumura, K., Kayashima, Y., Ishida, R., Kishimoto, N., Takahashi, M., Komori, T., Yamaguchi, Y., et al. (2021) · Autism Research · doi:10.1002/aur.2585 · Cited by 21
Sarejloo, S., Abadifard, E., Othman, Z. J., Zafarani, F., Khanzadeh, M., Sadigh‐Eteghad, S., Farajdokht, F., Mohammadpoorasl, A., & Khanzadeh, S. (2022) · Disease Markers · doi:10.1155/2022/5911408 · Cited by 22
Elbakary, N., Al‐Khuzaei, N., Hussain, T. A., Karawia, A., Smida, M., Abu-Rahma, N., Akel, F., Mahmoud, S. E., Currie, J., Khoodoruth, M. A. S., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119545 · Cited by 21
Chávez-Castillo, M., Nava, M., Ortega, Á., Rojas, M., Núñez, V., Salazar, J. J., Bermúdez, V., & Rojas, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200413144401 · Cited by 21
Dogaru, I.-A., Puiu, M. G., Manea, M., & Dionisie, V. (2022) · Brain Sciences · doi:10.3390/brainsci12101403 · Cited by 20
Ketamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 20
Okamoto, N., Hoshikawa, T., Honma, Y., Chibaatar, E., Ikenouchi, A., Harada, M., & Yoshimura, R. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01713-8 · Cited by 20
The multifaceted effects of fluoxetine treatment on cognitive functions
Ampuero, E., Luarte, A., Flores, F. S., Soto, A. I., Pino, C. H., Silva, V., Erlandsen, M., Concha, T., & Wyneken, Ú. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412420 · Cited by 23
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03031-6 · Cited by 23
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 20
How Does Repetitive Transcranial Magnetic Stimulation Influence the Brain in Depressive Disorders?
Taïb, S., Arbus, C., Sauvaget, A., Sporer, M., Schmitt, L., & Yrondi, A. (2018) · Journal of Ect · doi:10.1097/yct.0000000000000477 · Cited by 19
Sharpley, C. F., Bitsika, V., McMillan, M., Jesulola, E., & Agnew, L. L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s213839 · Cited by 19
Brás, J. P., Pinto, S. F. T., Almeida, M. I., Prata, J., von Doellinger, O., Coelho, R. C., Barbosa, M. A., & Santos, S. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_28 · Cited by 19
Paul, E. R., Östman, L., Heilig, M. A., Mayberg, H. S., & Hamilton, J. P. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02466-7 · Cited by 17
Branchi, I., Viglione, A., Vai, B., Cirulli, F., Benedetti, F., & Poggini, S. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103923 · Cited by 18
Fabrazzo, M., Cipolla, S., Pisaturo, M., Camerlengo, A., Bucci, P., Pezzella, P., Coppola, N., & Galderisi, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13121689 · Cited by 20
The role of T-lymphocytes in central nervous system diseases
Shen, J., Bian, N., Zhao, L., & Wei, J. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110904 · Cited by 20
Monoclonal antibody immunotherapy in psychiatric disorders
Miller, B. J., & Buckley, P. F. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30366-2 · Cited by 18
Castillo, M. F. R., Murata, S., Schwarz, M., Schütze, G. A., Moll, N., Martin, B., Burger, B., Weidinger, E., Mueller, N., & Halaris, A. E. (2019) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2019.03.005 · Cited by 17
Kim, H., Kim, J., & Jung, J. G. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5011 · Cited by 18
Postolache, T. T., Akram, F., Lee, E., Lowry, C. A., Stiller, J. W., Brenner, L. A., Streeten, E. A., Turecki, G., & Dwivedi, Y. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.027 · Cited by 19
Singh, A., Singh, L., Singh, P., & Bhatti, R. (2021) · ACS Omega · doi:10.1021/acsomega.0c04739 · Cited by 18
A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia
Büki, A., Kékesi, G., Horváth, G., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810016 · Cited by 18
Buchmann, A., Ritter, C. J., Müller, S. T., Haynes, M., Ghisleni, C., Tuura, R., & Hasler, G. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.017 · Cited by 18
Rossetti, A. C., Paladini, M. S., Brüning, C. A., Spero, V., Cattaneo, M. G., Racagni, G., Papp, M., Riva, M. A., & Molteni, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012453 · Cited by 17
Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood
Shin, S. H., & Kim, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_6 · Cited by 19
Beyer, D. K. E., Mattukat, A., & Freund, N. (2021) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-00212-2 · Cited by 18
Inhibition of acid sphingomyelinase increases regulatory T cells in humans
Wiese, T., Dennstädt, F., Hollmann, C., Stonawski, S., Wurst, C., Fink, J., Gorte, E., Mandasari, P., Domschke, K., Hommers, L. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab020 · Cited by 17
Rhein, C., Hepp, T., Kraus, O., von Majewski, K., Lieb, M., Rohleder, N., & Erim, Y. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02346-8 · Cited by 16
Segman, R. H., & Stein, M. B. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010063 · Cited by 17
Metadata
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
